Interaction between glutathione and apoptosis in systemic lupus erythematosus

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 741-751

  Shah, Dilip ^a   Sah, Sangita ^b   Nath, Swapan K ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Apoptosis; Glutathione; Reactive oxygen species; Redox state; Systemic lupus erythematosus (SLE)

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CATALASE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; MERCAPTAMINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

APOPTOSIS; CELL DEATH; DNA DAMAGE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; GLUTATHIONE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84877833856     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.12.007     Document Type: Review

References (137)

1. Amital H., Shoenfeld Y. Autoimmunity and autoimmune diseases such as systemic lupus erythematosus. Systemic lupus erythematosus 2004, 3-27. Elsevier Publication, Amsterdam, The Netherlands. 4th ed. G. Lahita Robert (Ed.).
2. Graham K.L., Utz P.J. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005, 17:513-517.
3. Kurien B.T., Scofield R.H. Free radical mediated peroxidative damage in systemic lupus erythematosus. Life Sci 2003, 73:1655-1666.
4. Munoz L.E., van Bavel C., Franz S., Berden J., Herrmann M., van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008, 17:371-375.
5. Franco R., Cidlowski J.A. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 2009, 16:1303-1314.
6. Griffiths H.R. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease?. Autoimmun Rev 2008, 7:544-549.
7. Ahsan H., Ali A., Ali R. Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol 2003, 131:398-404.
8. Mansour R.B., Lassoued S., Gargouri B., El Gaid A., Attia H., Fakhfakh F. Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 2008, 37:103-108.
9. Ben Mansour R., Lassoued S., Elgaied A., Haddouk S., Marzouk S., Bahloul Z., et al. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010, 39:247-253.
10. Valko M., Izakovic M., Mazur M., Rhodes C.J., Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004, 266:37-56.
11. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
12. Valko M., Rhodes C.J., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 160:1-40.
13. Kovacic P., Jacintho J.D. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem 2001, 8:773-796.
14. Ridnour L.A., Isenberg J.S., Espey M.G., Thomas D.D., Roberts D.D., Wink D.A. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A 2005, 102:13,147-13,152.
15. Vignais P.V. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 2002, 59:1428-1459.
16. Wei C.C., Wang Z.Q., Durra D., Hemann C., Hille R., Garcin E.D., et al. The three nitric-oxide synthases differ in their kinetics of tetrahydrobiopterin radical formation, heme-dioxy reduction, and arginine hydroxylation. J Biol Chem 2005, 280:8929-8935.
17. Turrens J.F., Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 1980, 191:421-427.
18. Chance B., Sies H., Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979, 59:527-605.
19. Suski J.M., Lebiedzinska M., Bonora M., Pinton P., Duszynski J., Wieckowski M.R. Relation between mitochondrial membrane potential and ROS formation. Methods Mol Biol 2012, 810:183-205.
20. Zahrt T.C., Deretic V. Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. Antioxid Redox Signal 2002, 4:141-159.
21. Nagy G., Koncz A., Telarico T., Fernandez D., Ersek B., Buzas E., et al. Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2010, 12:210.
22. Ahmad R., Rasheed Z., Ahsan H. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol Immunotoxicol 2009, 31:388-396.
23. Murphy M.P., Packer M.A., Scarlett J.L., Martin S.W. Peroxynitrite: a biologically significant oxidant. Gen Pharmacol 1998, 31:179-186.
24. Calcerrada P., Peluffo G., Radi R. Nitric oxide-derived oxidants with a focus on peroxynitrite: molecular targets, cellular responses and therapeutic implications. Curr Pharm Des 2011, 17:3905-3932.
25. Radi R., Peluffo G., Alvarez M.N., Naviliat M., Cayota A. Unraveling peroxynitrite formation in biological systems. Free Radic Biol Med 2001, 30:463-488.
26. Mena S., Ortega A., Estrela J.M. Oxidative stress in environmental-induced carcinogenesis. Mutat Res 2009, 674:36-44.
27. Ortona E., Margutti P., Matarrese P., Franconi F., Malorni W. Redox state, cell death and autoimmune diseases: a gender perspective. Autoimmun Rev 2008, 7:579-584.
28. Shadyro O.I., Yurkova I.L., Kisel M.A. Radiation-induced peroxidation and fragmentation of lipids in a model membrane. Int J Radiat Biol 2002, 78:211-217.
29. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991, 91:14S-22S.
30. Wiseman H., Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996, 313(Pt 1):17-29.
31. Stohs S.J., Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 1995, 18:321-336.
32. Lloyd R.V., Hanna P.M., Mason R.P. The origin of the hydroxyl radical oxygen in the Fenton reaction. Free Radic Biol Med 1997, 22:885-888.
33. Wanchu A., Khullar M., Deodhar S.D., Bambery P., Sud A. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int 1998, 18:41-43.
34. Gilkeson G., Cannon C., Oates J., Reilly C., Goldman D., Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999, 26:318-324.
35. Kurien B.T., Scofield R.H. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008, 7:567-573.
36. Kumagai S., Jikimoto T., Saegusa J. Pathological roles of oxidative stress in autoimmune diseases. Rinsho Byori 2003, 51:126-132.
37. Sundaresan M., Yu Z.X., Ferrans V.J., Irani K., Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995, 270:296-299.
38. Tsai K.J., Hung I.J., Chow C.K., Stern A., Chao S.S., Chiu D.T. Impaired production of nitric oxide, superoxide, and hydrogen peroxide in glucose 6-phosphate-dehydrogenase-deficient granulocytes. FEBS Lett 1998, 436:411-414.
39. Crane F.L., Low H. Reactive oxygen species generation at the plasma membrane for antibody control. Autoimmun Rev 2008, 7:518-522.
40. Lunec J., Herbert K., Blount S., Griffiths H.R., Emery P. 8-Hydroxydeoxyguanosine. A marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett 1994, 348:131-138.
41. Evans M.D., Cooke M.S., Akil M., Samanta A., Lunec J. Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Commun 2000, 273:894-898.
42. Morgan P.E., Sturgess A.D., Davies M.J. Evidence for chronically elevated serum protein oxidation in systemic lupus erythematosus patients. Free Radic Res 2009, 43:117-127.
43. Abou-Raya A., el-Hallous D., Fayed H. 8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus. Clin Invest Med 2004, 27:306-311.
44. Avalos I., Chung C.P., Oeser A., Milne G.L., Morrow J.D., Gebretsadik T., et al. Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Lupus 2007, 16:195-200.
45. Sheikh Z., Ahmad R., Sheikh N., Ali R. Enhanced recognition of reactive oxygen species damaged human serum albumin by circulating systemic lupus erythematosus autoantibodies. Autoimmunity 2007, 40:512-520.
46. Turgay M., Durak I., Erten S., Ertugrul E., Devrim E., Avci A., et al. Oxidative stress and antioxidant parameters in a Turkish group of patients with active and inactive systemic lupus erythematosus. APLAR J Rheumatol 2007, 10:101-106.
47. Kurien B.T., Scofield R.H. Lipid peroxidation in systemic lupus erythematosus. Indian J Exp Biol 2006, 44:349-356.
48. Shah D., Kiran R., Wanchu A., Bhatnagar A. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol Lett 2010, 129:7-12.
49. Turi S., Nemeth I., Torkos A., Saghy L., Varga I., Matkovics B., et al. Oxidative stress and antioxidant defense mechanism in glomerular diseases. Free Radic Biol Med 1997, 22:161-168.
50. Shah D., Aggarwal A., Bhatnagar A., Kiran R., Wanchu A. Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic Res 2011, 45:559-567.
51. Taysi S., Gul M., Sari R.A., Akcay F., Bakan N. Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 2002, 40:684-688.
52. Tewthanom K., Janwityanuchit S., Totemchockchyakarn K., Panomvana D. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythematosus: a pilot study from single center. J Pharm Pharm Sci 2008, 11:30-34.
53. Hassan S.Z., Gheita T.A., Kenawy S.A., Fahim A.T., El-Sorougy I.M., Abdou M.S. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis 2011, 14:325-331.
54. Young I.S., Woodside J.V. Antioxidants in health and disease. J Clin Pathol 2001, 54:176-186.
55. Michiels C., Raes M., Toussaint O., Remacle J. Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med 1994, 17:235-248.
56. Shah D., Kiran R., Wanchu A., Bhatnagar A. Relationship between T lymphocyte subsets and cortisol in systemic lupus erythematosus. Kathmandu Univ Med J (KUMJ) 2009, 7:213-219.
57. Shah D., Wanchu A., Bhatnagar A. Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 2011, 216:1010-1017.
58. D'Souza A., Kurien B.T., Rodgers R., Shenoi J., Kurono S., Matsumoto H., et al. Detection of catalase as a major protein target of the lipid peroxidation product 4-HNE and the lack of its genetic association as a risk factor in SLE. BMC Med Genet 2008, 9:62.
59. Franco R., Panayiotidis M.I., Cidlowski J.A. Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. J Biol Chem 2007, 282:30,452-30,465.
60. Ballatori N., Krance S.M., Notenboom S., Shi S., Tieu K., Hammond C.L. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009, 390:191-214.
61. Perl A., Gergely P., Banki K. Mitochondrial dysfunction in T cells of patients with systemic lupus erythematosus. Int Rev Immunol 2004, 23:293-313.
62. Circu M.L., Aw T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010, 48:749-762.
63. Circu M.L., Aw T.Y. Glutathione and apoptosis. Free Radic Res 2008, 42:689-706.
64. Cordova E.J., Velazquez-Cruz R., Centeno F., Baca V., Orozco L. The NRF2 gene variant, -653G/A, is associated with nephritis in childhood-onset systemic lupus erythematosus. Lupus 2010, 19:1237-1242.
65. Warchol T., Lianeri M., Wudarski M., Lacki J.K., Jagodzinski P.P. Catalase -262C>T polymorphism in systemic lupus erythematosus in Poland. Rheumatol Int 2008, 28:1035-1039.
66. Kiyohara C., Washio M., Horiuchi T., Asami T., Ide S., Atsumi T., et al. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of cigarette smoking and systemic lupus erythematosus in a Japanese population. Scand J Rheumatol 2012, 41:103-109.
67. Ollier W., Davies E., Snowden N., Alldersea J., Fryer A., Jones P., et al. Association of homozygosity for glutathione-S-transferase GSTM1 null alleles with the Ro+/La- autoantibody profile in patients with systemic lupus erythematosus. Arthritis Rheum 1996, 39:1763-1764.
68. Tew M.B., Ahn C.W., Friedman A.W., Reveille J.D., Tan F.K., Alarcon G.S., et al. Systemic lupus erythematosus in three ethnic groups. VIII. Lack of association of glutathione S-transferase null alleles with disease manifestations. Arthritis Rheum 2001, 44:981-983.
69. Halliwelly B., Gutteridge J.M.C. Free radical biology and medicine 2006, Clarendon Press, Oxford. 4 ed.
70. Sies H. Role of reactive oxygen species in biological processes. Klin Wochenschr 1991, 69:965-968.
71. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988, 263:17,205-17,208.
72. Bremer H.J., Duran M., Kameling J.P. Glutathione. Disturbances of amino acid metabolism: clinical chemistry and diagnosis 1981, 80-82. Urban & Schwarzenberg, Baltimore-Munich. H.J. Bremer, M. Duran, J.P. Kamerling (Eds.).
73. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001, 30:1191-1212.
74. Kemp M., Go Y.M., Jones D.P. Nonequilibrium thermodynamics of thiol/disulfide redox systems: a perspective on redox systems biology. Free Radic Biol Med 2008, 44:921-937.
75. Suthanthiran M., Anderson M.E., Sharma V.K., Meister A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc Natl Acad Sci U S A 1990, 87:3343-3347.
76. Huh Y.J., Kim J.M., Kim H., Song H., So H., Lee S.Y., et al. Regulation of osteoclast differentiation by the redox-dependent modulation of nuclear import of transcription factors. Cell Death Differ 2006, 13:1138-1146.
77. Sykes M.C., Mowbray A.L., Jo H. Reversible glutathiolation of caspase-3 by glutaredoxin as a novel redox signaling mechanism in tumor necrosis factor-alpha-induced cell death. Circ Res 2007, 100:152-154.
78. Hassan M.Q., Hadi R.A., Al-Rawi Z.S., Padron V.A., Stohs S.J. The glutathione defense system in the pathogenesis of rheumatoid arthritis. J Appl Toxicol 2001, 21:69-73.
79. Peterson J.D., Herzenberg L.A., Vasquez K., Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A 1998, 95:3071-3076.
80. Messina J.P., Lawrence D.A. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J Immunol 1989, 143:1974-1981.
81. Murata Y., Shimamura T., Hamuro J. The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int Immunol 2002, 14:201-212.
82. McCord J.M., Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969, 244:6049-6055.
83. Blum J., Fridovich I. Inactivation of glutathione peroxidase by superoxide radical. Arch Biochem Biophys 1985, 240:500-508.
84. Johnson F., Giulivi C. Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005, 26:340-352.
85. McCord J.M. Iron- and manganese-containing superoxide dismutases: structure, distribution, and evolutionary relationships. Adv Exp Med Biol 1976, 74:540-550.
86. Marklund S.L. Properties of extracellular superoxide dismutase from human lung. Biochem J 1984, 220:269-272.
87. Forman H.J., Fisher A.B. Antioxidant enzymes of rat granular pneumocytes. Constitutive levels and effect of hyperoxia. Lab Invest 1981, 45:1-6.
88. 2. Arch Biochem Biophys 1981, 210:505-516.
89. Aebi H. Catalase in vitro. Methods Enzymol 1984, 105:121-126.
90. Nilakantan V., Spear B.T., Glauert H.P. Liver-specific catalase expression in transgenic mice inhibits NF-kappaB activation and DNA synthesis induced by the peroxisome proliferator ciprofibrate. Carcinogenesis 1998, 19:631-637.
91. Gamble S.C., Wiseman A., Goldfarb P.S. Selenium-dependent glutathione peroxidase and other selenoproteins: their synthesis and biochemical roles. J Chem Technol Biotechnol 1999, 68:123-134.
92. Sen C.K. Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 2000, 36:1-30.
93. Lorenz H.M., Herrmann M., Winkler T., Gaipl U., Kalden J.R. Role of apoptosis in autoimmunity. Apoptosis 2000, 5:443-449.
94. Lorenz H.M., Herrmann M., Kalden J.R. The pathogenesis of autoimmune diseases. Scand J Clin Lab Invest Suppl 2001, 235:16-26.
95. Dieker J.W., van der Vlag J., Berden J.H. Deranged removal of apoptotic cells: its role in the genesis of lupus. Nephrol Dial Transplant 2004, 19:282-285.
96. Bijl M., Horst G., Limburg P.C., Kallenberg C.G. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 2001, 10:866-872.
97. Suzuki N., Ichino M., Mihara S., Kaneko S., Sakane T. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41:344-353.
98. Theofilopoulos A.N., Dixon F.J. Etiopathogenesis of murine SLE. Immunol Rev 1981, 55:179-216.
99. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994, 76:969-976.
100. McNally J., Yoo D.H., Drappa J., Chu J.L., Yagita H., Friedman S.M., et al. Fas ligand expression and function in systemic lupus erythematosus. J Immunol 1997, 159:4628-4636.
101. Gaipl U.S., Munoz L.E., Grossmayer G., Lauber K., Franz S., Sarter K., et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 2007, 28:114-121.
102. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946.
103. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A., Debatin K.M., Fischer A., et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349.
104. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263:1759-1762.
105. Robak E., Sysa-Jedrzejowska A., Robak T., Smolewski P. Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. Clin Rheumatol 2006, 25:225-233.
106. Emlen W., Niebur J., Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994, 152:3685-3692.
107. Dhir V., Singh A.P., Aggarwal A., Naik S., Misra R. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study. Lupus 2009, 18:785-791.
108. Xue C., Lan-Lan W., Bei C., Jie C., Wei-Hua F. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus. Cell Immunol 2006, 239:121-128.
109. Liphaus B.L., Kiss M.H., Carrasco S., Goldenstein-Schainberg C. Increased Fas and Bcl-2 expression on peripheral blood T and B lymphocytes from juvenile-onset systemic lupus erythematosus, but not from juvenile rheumatoid arthritis and juvenile dermatomyositis. Clin Dev Immunol 2006, 13:283-287.
110. Di Stefano A., Frosali S., Leonini A., Ettorre A., Priora R., Di Simplicio F.C., et al. GSH depletion, protein S-glutathionylation and mitochondrial transmembrane potential hyperpolarization are early events in initiation of cell death induced by a mixture of isothiazolinones in HL60 cells. Biochim Biophys Acta 2006, 1763:214-225.
111. Circu M.L., Aw T.Y. Glutathione and modulation of cell apoptosis. Biochim Biophys Acta 2012, 1823:1767-1777.
112. Jones D.P. Redefining oxidative stress. Antioxid Redox Signal 2006, 8:1865-1879.
113. Anathy V., Roberson E.C., Guala A.S., Godburn K.E., Budd R.C., Janssen-Heininger Y.M. Redox-based regulation of apoptosis: S-glutathionylation as a regulatory mechanism to control cell death. Antioxid Redox Signal 2012, 16:496-505.
114. Pierce G.B., Parchment R.E., Lewellyn A.L. Hydrogen peroxide as a mediator of programmed cell death in the blastocyst. Differentiation 1991, 46:181-186.
115. Devadas S., Hinshaw J.A., Zaritskaya L., Williams M.S. Fas-stimulated generation of reactive oxygen species or exogenous oxidative stress sensitize cells to Fas-mediated apoptosis. Free Radic Biol Med 2003, 35:648-661.
116. Perricone C., De Carolis C., Perricone R. Glutathione: a key player in autoimmunity. Autoimmun Rev 2009, 8:697-701.
117. Dalton T.P., Chen Y., Schneider S.N., Nebert D.W., Shertzer H.G. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic Biol Med 2004, 37:1511-1526.
118. Dalton T.P., Dieter M.Z., Yang Y., Shertzer H.G., Nebert D.W. Knockout of the mouse glutamate cysteine ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous. Biochem Biophys Res Commun 2000, 279:324-329.
119. Valverde M., Rojas E., Kala S.V., Kala G., Lieberman M.W. Survival and cell death in cells constitutively unable to synthesize glutathione. Mutat Res 2006, 594:172-180.
120. Hammond C.L., Lee T.K., Ballatori N. Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J Hepatol 2001, 34:946-954.
121. Ghibelli L., Fanelli C., Rotilio G., Lafavia E., Coppola S., Colussi C., et al. Rescue of cells from apoptosis by inhibition of active GSH extrusion. FASEB J 1998, 12:479-486.
122. Gouaze V., Andrieu-Abadie N., Cuvillier O., Malagarie-Cazenave S., Frisach M.F., Mirault M.E., et al. Glutathione peroxidase-1 protects from CD95-induced apoptosis. J Biol Chem 2002, 277:42,867-42,874.
123. Liuzzi F., Fanelli C., Ciriolo M.R., Cerella C., D'Alessio M., Denicola M., et al. Rescue of cells from apoptosis by antioxidants occurs downstream from GSH extrusion. Ann N Y Acad Sci 2003, 1010:441-445.
124. Sato T., Machida T., Takahashi S., Iyama S., Sato Y., Kuribayashi K., et al. Fas-mediated apoptosome formation is dependent on reactive oxygen species derived from mitochondrial permeability transition in Jurkat cells. J Immunol 2004, 173:285-296.
125. Armstrong J.S., Jones D.P. Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. FASEB J 2002, 16:1263-1265.
126. Varghese J., Khandre N.S., Sarin A. Caspase-3 activation is an early event and initiates apoptotic damage in a human leukemia cell line. Apoptosis 2003, 8:363-370.
127. Guha P., Dey A., Sen R., Chatterjee M., Chattopadhyay S., Bandyopadhyay S.K. Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. J Pharmacol Exp Ther 2011, 336:206-214.
128. Pan Z., Voehringer D.W., Meyn R.E. Analysis of redox regulation of cytochrome c-induced apoptosis in a cell-free system. Cell Death Differ 1999, 6:683-688.
129. Rudin C.M., Yang Z., Schumaker L.M., VanderWeele D.J., Newkirk K., Egorin M.J., et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003, 63:312-318.
130. Kane D.J., Sarafian T.A., Anton R., Hahn H., Gralla E.B., Valentine J.S., et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993, 262:1274-1277.
131. Voehringer D.W., Meyn R.E. Redox aspects of Bcl-2 function. Antioxid Redox Signal 2000, 2:537-550.
132. Zimmermann A.K., Loucks F.A., Schroeder E.K., Bouchard R.J., Tyler K.L., Linseman D.A. Glutathione binding to the Bcl-2 homology-3 domain groove: a molecular basis for Bcl-2 antioxidant function at mitochondria. J Biol Chem 2007, 282:29,296-29,304.
133. Bojes H.K., Datta K., Xu J., Chin A., Simonian P., Nunez G., et al. Bcl-xL overexpression attenuates glutathione depletion in FL5.12 cells following interleukin-3 withdrawal. Biochem J 1997, 325(Pt 2):315-319.
134. Suwannaroj S., Lagoo A., Keisler D., McMurray R.W. Antioxidants suppress mortality in the female NZB×NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 2001, 10:258-265.
135. Perricone C., De Carolis C., Giacomelli R., Greco E., Cipriani P., Ballanti E., et al. Inhibition of the complement system by glutathione: molecular mechanisms and potential therapeutic implications. Int J Immunopathol Pharmacol 2011, 24:63-68.
136. Li K.J., Wu C.H., Hsieh S.C., Lu M.C., Tsai C.Y., Yu C.L. Deranged bioenergetics and defective redox capacity in T lymphocytes and neutrophils are related to cellular dysfunction and increased oxidative stress in patients with active systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:548516.
137. Lai Z.W., Hanczko R., Bonilla E., Caza T.N., Clair B., Bartos A., et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012, 64:2937-2946.